Groupe Bruxelles Lambert SA Overview
GBL is one of continental Europe's oldest and largest listed investment holding companies. It is controlled by the Frère (Belgium) and Desmarais (Canada) families through Parjointco, which has a 47.8% voting interest. With a NAV of €13.1bn at June 2026 and an A1 Moody's rating, GBL is pivoting from a legacy portfolio of minority stakes in large European listed companies (SGS, Pernod Ricard, adidas, Imerys) towards controlled or co-controlled private companies. The private push is concentrated in healthcare (Affidea, Sanoptis, Rayner, and Recordati pending) and business services (BUKO). Under the November 2024 Strategic Update and new Managing Director Johannes Huth (ex-KKR), GBL targets three things:
-
double-digit annual TSR;
-
a stable €5.125 dividend per share (c.6–7% yield);
-
opportunistic buybacks, funded by €5bn+ of disposals.
The equity story has two parts. One is closing a persistent holding-company discount, which was 27.9% at end-2025. The other is whether GBL can prove private-equity-style value creation at scale while carrying zero net leverage.
Company's own description
GBL describes itself as an established investment holding company with over seventy years of stock-exchange listing. It calls itself a leading and active investor in Europe, focused on long-term value creation and backed by a stable family shareholder base. Its purpose statement, "delivering meaningful growth", promises shareholders attractive returns through three channels: growth in NAV per share, a sustainable dividend and share buybacks (H1 2026 press release, "About GBL").
Business model
GBL earns returns from four sources:
-
Dividends from listed and private holdings. These are the core of "cash earnings": €367m of net dividends out of €381m of FY2025 cash earnings.
-
Capital gains crystallised on disposals. Under IFRS 9 these do not pass through the consolidated net result for fair-value-through-OCI holdings. Examples: €164m on SGS and €(98)m on Umicore in FY2025.
-
Value creation in private assets, marked to fair value quarterly under IPEV guidelines. FY2025 value creation from direct private assets was +€641m.
-
Treasury income on gross cash: €51m of income on gross cash in FY2025.
The holding has minimal cost (other operating expenses within cash earnings were €(55)m in FY2025). It funds itself with institutional bonds, a convertible bond into GBL shares, and committed undrawn credit lines (€2.45bn, maturing 2030).
Revenue model (product vs service vs subscription vs licensing)
| Consolidated turnover component, FY2025 (EUR Mn) | Nature | Amount | % of consolidated turnover |
|---|---|---|---|
| Imerys | Industrial minerals products | 3,383.7 | 54.4 |
| Affidea | Healthcare services (diagnostics/outpatient) | 1,248.0 | 20.1 |
| Sanoptis | Healthcare services (ophthalmology) | 773.3 | 12.4 |
| Canyon | Consumer products (D2C bicycles) | 771.7 | 12.4 |
| GBL Capital / Sienna IM | Asset management fees and consolidated funds | 45.0 | 0.7 |
| Total | — | 6,221.7 | 100.0 |
This framework does not apply directly to GBL. At the holding level, "revenue" consists of dividends, interest and realised gains. On a consolidated IFRS basis, turnover (€6,222m in FY2025) is the sales of controlled companies:
Source: GBL FY2025 Results, Appendix B.4 (IFRS segment table). On this view the consolidated mix is roughly 54% product (Imerys), 33% services (healthcare), 12% D2C product (Canyon) and about 1% fees. BUKO (services, c.€230m revenue per Manda.be) has been consolidated from July 2026.
Value-chain position, customers and end-markets
GBL sits at the capital-allocation layer of the value chain. Its customers are its shareholders and, indirectly, the end-customers of its portfolio companies. End-market exposure by asset at end-2025 and mid-2026:
Healthcare services: diagnostic imaging, laboratory, outpatient and cancer care (Affidea); ophthalmic surgery and diagnostics (Sanoptis).
MedTech: intraocular lenses and ophthalmic consumables (Rayner).
Specialty pharma: rare diseases and primary/specialty care (Recordati, pending).
Testing, inspection and certification (TIC): SGS.
Premium spirits: Pernod Ricard.
Sportswear: adidas.
Industrial specialty minerals: Imerys.
Customer-experience outsourcing: Concentrix.
Premium bicycles: Canyon.
Mobile gaming: Voodoo.
Leisure parks: Parques Reunidos.
Temporary traffic management: BUKO.
Hygiene products: Ontex.
Independent characterisation
GBL is in mid-transformation from a passive "Belgian blue-chip conglomerate" into a hybrid closer to a family-backed private-equity firm with permanent capital. That model resembles Investor AB's Patricia Industries or Exor's private-asset arm. The 2024–2027 plan has three pillars:
-
simplification, with over €5bn of disposals achieved by H1 2026;
-
concentration in controlled or co-controlled direct private assets, which rose from 32% of the portfolio at end-2025 to 37% at Q1 2026 before the BUKO and Recordati investments;
-
capital return.
The key analytical tension is valuation and disclosure. Private assets are carried at manager marks, while the market applies a 20–30% discount. The listed legacy book has also been a persistent drag on NAV: Pernod Ricard's fair value fell €619m in FY2025 and adidas €430m.
Strategy
Stated strategy (2024–2027 mid-term plan, Strategic Update of 7 Nov 2024)
GBL's FY2025, Q1 2026 and H1 2026 presentations group the strategy into three priorities:
-
Portfolio simplification: €5bn of disposals targeted over 2024–2027. More than €5bn had been achieved by H1 2026: adidas €1.7bn (2024); GBL Capital €1.7bn, SGS €0.8bn and Umicore €0.3bn (2025); Umicore €0.3bn, Concentrix €0.1bn and non-core €0.2bn (H1 2026).
-
Focus on direct private assets: priority to controlled or co-controlled investments in growing markets, and an increased weight of direct private assets. Test-Achats (May 2025) reports an aim of roughly 50% listed / 50% private by 2027.
-
Attractive returns to shareholders: double-digit annual TSR, a sustainable dividend and share buybacks.
Purpose statement: "Delivering meaningful growth".
Medium-term targets and guidance
| Target | Status (latest) |
|---|---|
| Double-digit annual TSR | 23.2% (FY2025); 17.5% (12 months to June 2026) |
| €5bn disposals 2024–2027 | Exceeded by H1 2026 |
| Dividend per share | €5.125 for FY2025 (paid 18 May 2026); to be held stable "for the foreseeable future" |
| Share buybacks | Opportunistic; eighth envelope 30.4% executed at 10 Mar 2026; 3.4m shares cancelled May 2026 |
| LTV | Below historical 10% upper limit; currently 0.0% |
Strategic initiatives in the last 24 months
| Date | Initiative | Detail |
|---|---|---|
| Nov 2024 | Strategic Update | New plan; dividend reset to €5.00 (+82%) |
| Mar–May 2025 | Governance transition | Huth as Managing Director, Gallienne as Chairman |
| Q1 2025 | SGS partial sale | €0.8bn |
| Oct 2025 | Affidea €150m equity injection | Growth acceleration |
| Q4 2025 | GBL Capital secondary sale and run-off | €1.7bn proceeds; €0.6bn of unfunded commitments transferred |
| Dec 2025 – Feb 2026 | Sienna IM disposal | Exit of third-party asset management |
| 2,025 | Canyon reorganisation | Cost and organisational adaptation |
| Jan 2026 | Team build-out | Two Investment Partners; Technology added as a sector |
| Feb–May 2026 | Rayner | €0.5bn, 45% co-control |
| Apr–Jul 2026 | BUKO | c.€0.5bn, controlling stake; business-services platform |
| May 2026 → | Recordati take-private with CVC | GBL's largest healthcare investment to date |
| Jan and Aug 2026 | Balance-sheet financing | Two €500m bonds (10-year 3.75%; 8-year) |
| Ongoing | GBL ACT | Solidarity / philanthropic engagement programme (AGM 2026 agenda item) |
ESG and sustainability commitments
Science-based GHG targets were validated by SBTi in January 2022 (GBL FY2021 Results). GBL publishes an ESRS-aligned Sustainability Statement as Volume 2 of its Annual Report 2025, with limited assurance by PwC.
Products & Services
For an investment holding, the "product catalogue" is the investment portfolio. Each holding is profiled below.
Listed assets (NAV at 31 Dec 2025)
| Holding | Business | GBL stake (% capital) | Share price 31-Dec-25 (EUR) | NAV EUR Mn 31-Dec-25 | NAV EUR Mn 31-Dec-24 | FY2025 TSR (%) | Notes |
|---|---|---|---|---|---|---|---|
| SGS | World leader in testing, inspection and certification | 14.34 | 97.55 | 2,725 | 3,501 | 4.9 | €0.8bn partial sale Q1 2025; 5.6% organic growth in 2025, 24 acquisitions including Applied Technical Services (US) |
| Pernod Ricard | Global #2 spirits and wines | 6.83 | 73.10 | 1,260 | 1,879 | -29.2 | Tariff and inventory headwinds; €1bn efficiency plan FY26–FY29; targets 3–6% organic growth FY27–FY29 |
| Imerys | World #1 specialty minerals (consolidated at 55%) | 54.72 | 23.94 | 1,113 | 1,311 | -11.0 | 2025 revenue €3.385bn; adjusted EBITDA €546m; €467m goodwill impairment; Project Horizon targets €50–60m of savings |
| adidas | Global #2 sportswear | 3.53 | 169.05 | 1,075 | 1,496 | -28.0 | 2025 brand sales +13% currency-neutral; operating margin 8.3%; up to €1bn buyback in 2026 |
| Umicore | Materials technology and recycling | 7.96 (exited Feb 2026) | 17.90 | 351 | 391 | 85.3 | Fully exited 25 Feb 2026 (c.19.6m shares, €0.3bn) |
| Concentrix | CX outsourcing (Webhelp combination) | 14.09 | 35.39 (USD converted) | 314 | 371 | -13.0 | €0.1bn disposed in H1 2026 |
| Ontex | Personal hygiene products | 19.98 | 4.90 | 81 | 138 | -41.6 | Small legacy position |
| TotalEnergies | Integrated energy | 0.01 | 55.59 | 7 | 14 | 12.0 | Residual |
| GEA | Food processing machinery | 0.07 | 57.80 | 6 | 5 | 23.3 | Residual |
Source: GBL FY2025 Results, Appendix A.1 and A.2; Imerys FY2025 release. At Q1 2026, SGS was c.44% of listed NAV, Pernod 19%, Imerys 17% and adidas 15% (Kalkine, citing the GBL Q1 2026 report).
Direct private assets
| Asset | Description | Entry | GBL stake | NAV 31-Dec-25 (EUR Mn) | Key operating facts |
|---|---|---|---|---|---|
| Affidea | Pan-European provider of advanced diagnostics, outpatient services, lab testing and cancer care | July 2022 | 99.16% | 2,140 | FY2025 sales €1,224m (+17%, +6% organic); 418 locations; 35.0m examinations; 18 acquisitions in 2025 (IHZD pathology and Uroviva urology in Switzerland); €150m equity injection Oct 2025; LabPoint (Switzerland) acquired early 2026; AI roll-out across clinics |
| Sanoptis | European leader in ophthalmology services (surgery and diagnostics) | July 2022 | 84.34% (69.87% fully diluted) | 1,105 | FY2025 sales €813m (+18%, +8% organic); 468 locations; 959 doctors; 5,207 employees; 3.7m treatments; present in Switzerland, Germany, Spain, Italy, Austria and Greece |
| Canyon | World's largest direct-to-consumer manufacturer of premium bikes (Koblenz, Germany) | March 2021 | 52.35% | 267 | FY2025 sales €738m (-6%); EBITDA -34%; e-MTB quality suspensions (Q4 2024) completed; organisational restructuring; new Koblenz e-bike store in 2026 |
| Voodoo | Leading mobile game publisher by downloads (France) | 2021 (minority) | 14.93% | 314 | FY2025 sales €689m (+11%) |
| Parques Reunidos | European leisure-park operator | 2017 (minority; private since 2019) | 23.00% | 281 | US business sold (March 2025 announcement); FY2025 sales €549m (-36% reported, broadly stable like-for-like); refinanced and paid a dividend |
| Rayner (new) | UK-based maker of intraocular lenses (IOLs), ophthalmic consumables (OMIDRIA, Ophteis OVDs), SOPHI phaco platform and digital tools; operates in 80+ countries | Signed 9 Feb 2026; closed 28 May 2026 | 45% co-control with CVC | €0.5bn equity (held at cost) | Galaxy spiral IOL launch expected Q4 2026; EMV and EMV toric lenses recently approved in North America (CVC; Insight News) |
| BUKO Group (new) | Temporary traffic management (TTM): design and planning, permits, deployment and collection of signage, on-site management, digital traffic solutions | Signed 23 Apr 2026; closed 8 Jul 2026 | Majority/controlling | c.€0.5bn equity (Manda.be: €500m) | Founded in the Netherlands in 1991; c.1,000 employees; operations in the Netherlands, Sweden, the UK and Germany; c.€230m revenue; bolt-ons include Keltic (London), Road Traffic Solutions and BVT Bremer Verkehrstechnik; Beverwijk HQ |
| Recordati (pending) | Italian specialty pharma: rare diseases (e.g. Isturisa for Cushing's), specialty and primary care, self-medication, APIs | Tender announced 22 May 2026 (with CVC Fund IX) | Co-control with CVC; GBL already holds c.3.25% (Mergermarket) | Equity commitment up to c.10% of 31-Mar-26 NAV (Zonebourse), i.e. c.€1.3bn | 2025 revenue €2.62bn; Q1 2026 revenue €713.4m (+4.9%); c.4,700 employees; offer raised to €53/share in Oct 2026 |
Non-core asset classes
| Asset | Description | NAV 31-Dec-25 (EUR Mn) | Status |
|---|---|---|---|
| GBL Capital | Funds (e.g. ICONIQ, Human Capital, 468 Capital, Sagard, Griffin, Kartesia, Backed) and co-investments (Flora Food Group €224.6m, Proalpha €71.9m, Commure €39.9m, Transcarent €17.7m), Sienna-branded funds | 1666 (of which cash and working capital €590.6m) | Large secondary sale (€1.7bn proceeds; €0.5bn deferred 12 months); no new commitments; remaining unfunded commitments €238m |
| Sienna Investment Managers | Third-party asset management (Sienna Gestion, Sienna Private Credit, Sienna Real Estate) | 61 | Sale agreements signed Dec 2025 and Feb 2026; FY2025 net economic result €(69)m |
Source: GBL FY2025 Results, Appendix A.4–A.5: ### Pricing model
Not applicable at holding level. GBL charges no fees to its own shareholders. Sienna IM earned €127m in FY2025 revenues, including €11m of fees from GBL Capital, before its disposal.
Financial Narrative
Holding-company key performance indicators (primary metrics)
Sources: FY2021: GBL FY2021 Results (10 Mar 2022): - FY2022: GBL FY2022 Results (9 Mar 2023).
-
FY2023: GBL FY2023 Results, including economic presentation (cash earnings €414.1m, net result €1,723.2m, basic EPS €12.28; FY2022 EPS €(3.99)).
-
FY2024–FY2025: GBL FY2025 Results.
-
Discounts for 2021–2023 are computed as 1 − price/NAV per share; 2024–2025 are as reported by GBL.
Leverage indicators (partial history)
Sources: GBL FY2021 Results; GBL FY2025 Results Appendix B.2; RTTNews and GBL H1 2026 release. The FY2022 LTV was 15.7% at end-September 2022 before the pro-forma Holcim forward sales (GBL FY2022 release).
IFRS consolidated figures (template metrics, heavily qualified)
Sources: GBL FY2025 Results Appendix B.4; GBL H1 2025 economic presentation; RTTNews and Simply Wall St (H1 2026 sales €3,359.3m).
Gross profit, operating income, EBITDA and IFRS margins at group level are not presented by GBL and would be economically misleading. They mix Imerys's industrial P&L with holding-level fair-value effects. FY2025 consolidated EBITDA is therefore "not publicly disclosed" as a GBL KPI.
The FY2025 IFRS lines allow a rough proxy. Turnover €6,221.7m less raw materials €1,906.9m, employee expenses €1,920.7m and other operating expenses €1,359.9m gives an operating-company EBITDA proxy of about €1,034m. This is an analyst calculation, not a company figure. Depreciation was €606.0m and impairments €545.6m.
Cash earnings composition
Source: GBL FY2025 Results, Appendix B.3: ### Cash flow: notes and sources
Source: GBL FY2025 Results, Appendix B.1: "Free cash flow" in the conventional sense is not a GBL metric. Cash earnings minus the dividend paid was about €(284)m in FY2025. The dividend, at €5.125 per share on c.120m shares outstanding net of treasury, costs c.€615–680m a year, which is above recurring cash earnings. The gap is funded by disposals. This is a structural point for Section 22.
Shareholder returns history
Sources: GBL FY2021, FY2022, FY2023 results; Power Corporation 2023 GBL page (€816m buybacks, €402m dividends in 2023); GBL FY2025 Results. H1 2026 cash returns totalled €773m (dividend plus buybacks; GBL H1 2026).
Trend commentary
NAV erosion (2021–2025). NAV fell from €22.5bn to €14.0bn, and NAV per share from €143.91 to €105.37 (−27%). Four forces drove this:
-
the 2022 market drawdown (−19% NAV per share);
-
persistent de-rating of the consumer holdings, with Pernod Ricard −33% and adidas −28% in fair value in FY2025 alone;
-
distributions and buybacks that shrink absolute NAV;
-
GBL Capital write-downs on the 2025 secondary sale, with €(381)m of IFRS result contribution.
Inflection points.
-
2023: the Webhelp–Concentrix deconsolidation produced a €1.29bn gain and the record €1,723m net result.
-
2024: the dividend was reset to €5.00.
-
2025: GBL moved to net cash, and the discount narrowed from 41.7% to 27.9% as the new strategy gained credibility.
Cash earnings. These fell from €474m (2021) to €336m (2024) as dividend-paying listed stakes were sold and the Concentrix note was monetised. They recovered to €381m in 2025 on treasury income (€51m from gross cash) and the GBL Capital dividend (€89m). H1 2026 cash earnings of €296m (H1 2025: €320m) show the dilutive effect of selling dividend payers (SGS, Umicore) to buy growth assets, which pay no dividend.
IFRS volatility. The consolidated net result swings with Imerys impairments, GBL Capital mark-to-market and deconsolidation gains. It is not a reliable signal of underlying value creation.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Asset class (EUR Mn)
| Asset class (EUR Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Listed assets NAV (EUR Mn) | 16,933 | 12,450 | — | 9,105 | 6,931 |
Direct private assets NAV (EUR Mn) | — | — | — | 3,305 | 4,106 |
GBL Capital NAV (EUR Mn) | — | 2,535 | 2,951 | 2,743 | 1,666 |
Sienna Investment Managers NAV (EUR Mn) | — | — | — | 137 | 61 |
Total portfolio (EUR Mn) | 22,713 | 19,535 | — | 15,290 | 12,765 |
Asset class mix (% of portfolio)
| Asset class mix (% of portfolio) | FY2025 | Q1 2026 |
|---|---|---|
Listed assets | 54 | 52 |
Direct private assets | 32 | 37 |
Non-core (GBL Capital and Sienna IM) | 14 | 10 |
Ifrs Segment, FY2025 Details
| IFRS segment, FY2025 (EUR Mn) | Turnover | Pre-tax profit from consolidated operations | Profit attributable to group |
|---|---|---|---|
Holding | 0 | 71.8 (investing activities) | 71.5 |
Imerys | 3,383.7 | -381.5 | -224.8 |
Canyon | 771.7 | -25.1 | -5.5 |
Affidea | 1,248.0 | 74.3 | 53.7 |
Sanoptis | 773.3 | -97.3 | -70.9 |
GBL Capital / Sienna IM | 45.0 | -4.6 (operating); -141.9 (investing) | -449.4 |
Group total | 6,221.7 | -434.2 (operating) | -625.4 |
Segment Revenue
| Metric | Affidea | Sanoptis | Canyon | Total |
|---|---|---|---|---|
Sales FY2025 (EUR Mn) | 1,224 | 813 | 738 | 2,775 |
Sales growth (%) | 17 | 18 | -6 | 10 |
Organic growth (%) | 6 | 8 | -6 | 2 |
EBITDA growth (%) | 35 | 18 | -34 | 20 |
GBL ownership (%) | 99.16 | 84.34 | 52.35 | — |
NAV 31 Dec 2025 (EUR Mn) | 2,140 | 1,105 | 267 | 3,512 |
MoIC (x) | 1.9 | 1.5 | 0.7 | — |
Key Financials and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net asset value (EUR Mn) | 22,501 | 17,775 | 16,671 | 15,681 | 14,035 |
NAV per share (EUR) | 143.91 | 116.18 | 113.64 | 113.30 | 105.37 |
Year-end share price (EUR) | 98.16 | 74.58 | 71.22 | 66.05 | 75.95 |
Discount to NAV (%) | 31.8 | 35.8 | 37.3 | 41.7 | 27.9 |
Cash earnings (EUR Mn) | 474 | 416 | 414 | 336 | 381 |
Consolidated net result, group share (EUR Mn) | 279 | -585 | 1,723 | 132 | -625 |
Basic EPS (EUR) | 1.83 | -3.99 | 12.28 | 0.99 | -4.94 |
Dividend per share for the year (EUR) | 2.75 | 2.75 | 2.75 | 5.00 | 5.125 |
Gross cash excl. treasury shares (EUR Mn) | 2,293 | 1,397 | 1,080 | 2,606 | 2,393 |
Key Financials and Margin Analysis (%)
| Metric | FY2021 | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|---|
Net cash / (net debt) (EUR Mn) | -990 | -460 | 333 | not disclosed in retrieved release (LTV 0.0%) |
Loan to value (%) | 4.3 | 3.0 | 0.0 | 0.0 |
Gross debt (EUR Mn) | — | 3,070 | 2,061 | — |
Liquidity profile (EUR Mn) | — | 5,056 | 4,843 | c.4600 |
Undrawn committed credit lines (EUR Mn) | — | — | 2,450 | c.2500 |
Key Financials
| Metric | FY2024 | FY2025 | H1 2025 | H1 2026 |
|---|---|---|---|---|
Consolidated turnover (EUR Mn) | 6,055.7 | 6,221.7 | — | 3,359.3 |
Consolidated profit for the period, total (EUR Mn) | 63.2 | -833.6 | — | — |
Net result, group share (EUR Mn) | 132.3 | -625.4 | 44.0 | 53.5 |
Cash earnings (EUR Mn) | 336.2 | 381.3 | 320.2 | 296 |
Components
| Component (EUR Mn) | FY2024 | FY2025 |
|---|---|---|
Net dividends from investments | 388.9 | 367.4 |
Interest income (expenses) | -9.9 | 18.2 |
Other financial income (expenses) | 10.8 | 51.0 |
Other operating income (expenses) | -55.0 | -55.1 |
Gains on disposals | 1.6 | 0.0 |
Taxes | -0.1 | -0.3 |
Cash earnings total | 336.2 | 381.3 |
Dividend received by source (EUR Mn)
| Dividend received by source (EUR Mn) | FY2024 | FY2025 |
|---|---|---|
SGS | 125.6 | 98.1 |
GBL Capital | 71.5 | 89.3 |
Pernod Ricard | 81.0 | 81.0 |
Imerys | 62.6 | 67.4 |
adidas | 6.3 | 10.8 |
Concentrix | 9.5 | 10.1 |
Umicore | 31.4 | 9.8 |
TotalEnergies | 0.7 | 0.7 |
Total | 388.9 | 367.4 |
Financial Analysis
| Item | FY2025 |
|---|---|
Opening net debt | -460.2 |
Cash earnings | 381.3 |
Dividend paid for FY2024 | -665.7 |
Investments (total) | -545.5 |
— of which GBL share buybacks | -334.9 |
— of which Affidea | -149.0 |
— of which Canyon | -19.8 |
— of which Sanoptis | -16.7 |
— of which SGS (scrip) / adidas | -25.1 |
Divestments / distributions | 2,397.3 |
— of which GBL Capital net distributions | 1,293.3 |
— of which SGS | 772.1 |
— of which Umicore | 299.3 |
Other (timing, LTIP/carry revaluation) | -774.4 |
Closing net cash | 332.8 |
Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2025 |
|---|---|---|---|---|
Share buybacks (EUR Mn) | 407 | 643 | 816 | 335 |
Dividends paid in year (EUR Mn) | — | — | 402 | 666 |
Financial Analysis (FY2025 value)
| Ratio | FY2025 value | Comment |
|---|---|---|
Return on NAV per share (NAV/share change + dividend) | c.-2.6% (105.37 − 113.30 + 5.00 paid = −2.93 on 113.30) | Analyst calculation |
TSR (company-reported) | 23.2% (FY2025); 17.5% (12 months to June 2026) | Rerating-driven (discount narrowed 1,378 bps) |
ROE (IFRS) | Negative (net result €(625)m) | — |
ROA, ROIC, asset turnover, cash conversion cycle | Not meaningful / not publicly disclosed for the holding | — |
Current ratio | Not publicly disclosed in retrieved sources | — |
Debt / equity | Gross debt €2,061m vs NAV €14,035m = 14.7% (FY2025) | NAV used as an equity proxy |
Net debt / EBITDA | Not applicable (net cash) | — |
Loan to value | 0.0% (FY2025 and H1 2026) | Upper limit historically 10% |
Interest coverage (cash) | Net dividends €367m vs bond/exchangeable interest €52m ≈ 7.1x | Analyst calculation from FY2025 Results |
Weighted average debt maturity | 4.1 years (Dec 2025) vs 3.6 (Dec 2024) | Extended by 2026 bonds |
Holding Details
| Holding | Primary geographies |
|---|---|
Affidea | Pan-European (418 locations). Switzerland is significantly expanded (IHZD, Uroviva, LabPoint). Hungary is being disposed of: 2025 reported sales exclude Hungary, and growth excluding Hungary exceeded 20% |
Sanoptis | Switzerland and Germany (core), plus Spain (4 centres), Italy (7), Austria (5) and Greece (4) |
Canyon | Europe (largest market by far); Asia and US subdued, with US tariff uncertainty |
BUKO | Netherlands, Sweden, UK (expanded via Keltic in London), Germany |
Rayner | UK HQ; 80+ countries; North American expansion; Asia and Latin America growth |
Recordati | Global specialty pharma (Italy HQ); rare-disease franchise global |
SGS | Global TIC; North American presence doubled via Applied Technical Services (SGS target of doubling North American sales is 80% achieved) |
Parques Reunidos | Europe-only after the 2025 US disposal |
Imerys | Global industrial minerals (EMEA, Americas, APAC) |
Share Price and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Year-end share price (EUR) | 98.16 | 74.58 | 71.22 | 66.05 | 75.95 |
Dividend per share for fiscal year (EUR) | 2.75 | 2.75 | 2.75 | 5.00 | 5.125 |
Dividend yield on year-end price (%) | 2.8 | 3.7 | 3.9 | 7.6 | 6.7 |
NAV per share (EUR) | 143.91 | 116.18 | 113.64 | 113.30 | 105.37 |
Share Price & Returns
| Horizon | Performance | Source |
|---|---|---|
YTD 2026 (to ~mid-Oct) | c.+8.6% price (€75.95 → c.€82.5, eToro, Oct 2026) | Analyst calculation; date-sensitive |
1-year TSR | 17.5% (June 2025 → June 2026, company-reported); c.13.9% (Simply Wall St, Aug 2026) | GBL H1 2026; Simply Wall St |
3-year | Price from €71.22 (YE2023) to c.€82.5: c.+16% before dividends | Analyst calculation |
5-year total return | c.5.8% cumulative (Simply Wall St, Aug 2026) | Third-party |
52-week range | c.€71.60–€85.25 (TipRanks, Frankfurt line) | Third-party |
Long-run | Annualised TSR 6.4% from 2012 to 30 Sept 2024 vs 9.2% for the Stoxx Europe 50 (GBL website, 2024) | GBL |
Valuation Snapshot
| Metric | Value |
|---|---|
Price / NAV per share | c.0.82x (€82.5 / €100.77 at June 2026), a c.18% discount; 0.72x at YE2025 (27.9% discount) |
Price / sales (consolidated) | c.1.4x (Simply Wall St, Aug 2026) |
Price / book (IFRS) | c.0.72x (Fintel, July 2026) |
Dividend yield | c.6.2% at €82.5 (€5.125 / €82.5) |
Analyst consensus | TipRanks labels the stock "undervalued" without a disclosed target |
Credit Ratings
| Agency | Rating | Outlook | Date |
|---|---|---|---|
Moody's | A1 | Stable | Confirmed June 2026 |
Capital Instruments
| Instrument (EUR Mn) | 31-Dec-2024 | 31-Dec-2025 |
|---|---|---|
Institutional bonds | 2,000 | 1,500 |
Exchangeable bonds into Pernod Ricard shares | 500 | 0 |
Convertible bonds into GBL shares | 500 | 500 |
Other | 70 | 61 |
Gross debt | 3,070 | 2,061 |
Analyst Conclusions
Management guidance
GBL reiterates double-digit annual TSR, driven by NAV-per-share growth, a stable €5.125 dividend and ongoing buybacks (H1 2026; RTTNews). It also commits to continued portfolio simplification and to raising the share of controlled or co-controlled direct private assets. It provides no earnings guidance, which is customary for holdings.
Bull case
-
Discount compression has room to run. It narrowed from 41.7% to 27.9% in 2025 and to roughly 18% by October 2026. Continued buybacks (8% treasury shares), cancellations and proof of private-asset value could move GBL toward the low-teens discounts of best-in-class peers.
-
The healthcare franchise compounds. Affidea (+17% sales, +35% EBITDA in FY2025), Sanoptis (+18% sales) and Rayner (Galaxy launch in Q4 2026, US growth) make up a growing share of NAV. Recordati adds a high-margin rare-disease asset bought alongside an incumbent controller with deep knowledge of the company.
-
Firepower without leverage. LTV of 0.0%, €4.6bn of liquidity and an A1 rating allow counter-cyclical deployment and buybacks at the same time.
Bear case
-
NAV per share keeps falling. It went from €143.91 (2021) to €100.77 (H1 2026), and the legacy consumer stakes (Pernod, adidas) and Imerys remain exposed to tariffs and industrial weakness.
-
The dividend outruns recurring income. FY2025 cash earnings were €381m against a €666m dividend paid. H1 2026 cash earnings fell as dividend payers were swapped for non-dividend private assets, so the payout depends on continued disposals.
-
Deal-price discipline is in question. The Recordati price was raised under activist pressure. Two co-controlled CVC assets concentrate counterparty and exit-timing risk. Canyon (0.7x MoIC) shows that private-asset marks can disappoint.
Catalysts and monitorables (next 12 months)
Recordati tender outcome: acceptance closes 23 October 2026; payment 2 November 2026. Watch whether the 66.67% threshold is met or waived, the delisting route, and GBL's final equity cheque.
Q3 2026 results: on 5 November 2026: NAV per share, cash earnings, and the first BUKO contribution.
FY2026 results (around March 2027): dividend confirmation at €5.125, value-creation marks for Rayner and BUKO after the 12-month cost-hold period, and disclosure on the remaining Concentrix and GBL Capital positions.
Rayner Galaxy IOL launch: (expected Q4 2026).
-
Pernod Ricard tariff and recovery trajectory; adidas growth; Imerys Project Horizon savings.
-
Closing of the Sienna Gestion and Sienna Private Credit sales.
-
Pace of buybacks and the next share cancellation at the 2027 EGM.
-
Any update to the mid-term plan as the 2024–2027 horizon nears its end, including portfolio-mix targets.
Analyst verdict
GBL in late 2026 is a credible but unfinished turnaround. The new leadership has done the easy and necessary part well, and quickly:
-
more than €5bn of disposals ahead of the 2027 deadline;
-
the exit from distracting third-party asset management;
-
a net-cash balance sheet with an A1 rating;
-
a dividend reset that now yields about 6%.
The market has rewarded this. The discount to NAV has roughly halved from its late-2024 peak, and twelve-month TSR is in double digits, as promised.
The hard part is now under way. GBL has committed about €2.3bn to Rayner, BUKO and Recordati, with more possible. That capital must compound at private-equity-like rates to reverse a multi-year decline in NAV per share. The early evidence is mixed. Affidea and Sanoptis demonstrate real buy-and-build skill (1.9x and 1.5x MoIC). Canyon shows how consumer cyclicality can hurt a direct-ownership model. The decision to raise the Recordati price, despite a waivable acceptance threshold, will be read as a test of discipline. The structural mismatch between recurring cash earnings and a €5.125 dividend also means the payout is effectively funded by realisations.
Downside is cushioned by a clean balance sheet, family sponsorship, a high yield and a still-meaningful discount of about 18%. Upside depends on evidence over the next four to six quarters that the private portfolio, now heavily weighted to European healthcare, generates mark-to-market and eventually cash value creation that offsets volatility in the residual listed book. The key monitorables are three:
-
NAV per share growth, ex-dividend, turning positive on a trailing twelve-month basis;
-
the first value-creation marks on Rayner and BUKO;
-
the execution and pricing outcome of Recordati.
If these line up, a further narrowing of the discount toward peer levels is plausible. If they do not, GBL risks reverting to a high-yield, low-growth holding whose discount re-widens.
Data gaps flagged (not publicly disclosed in sources retrieved):
-
holding-level headcount;
-
detailed executive compensation;
-
full board roster with independence and committee data;
-
top-10 institutional holders;
-
geographic revenue split;
-
FY2021–FY2023 consolidated turnover and IFRS margins;
-
FY2022–FY2023 net debt;
-
FY2024 buyback amount;
-
S&P and Fitch ratings;
-
ESG ratings;
-
peer quantitative benchmarks;
-
the bond maturity ladder;
-
the coupon on the August 2026 bond.
These should be completed from GBL's Annual Report 2025 (Vol. 1 and 2) and the Half-year Report 2026 PDFs.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Notes |
|---|---|---|---|---|
Johannes Huth | Managing Director (Administrateur-Délégué; effectively CEO) | Since 2 May 2025 | 25 years at KKR (from 1999), most recently Partner and Chairman of KKR EMEA, then Senior Advisory Partner (2024); Investcorp management committee 1991–1999; Salomon Brothers M&A 1986–1991 (London, New York) | Board member of Imerys, Axel Springer SE and Marshall Wace; chairs LSE's Finance and Estates Committee; Chevalier des Arts et Lettres 2025 (GBL release 13 Mar 2025; LSE governance page) |
Xavier Likin | Chief Financial Officer | — | — | GBL press-release contact |
Alison Donohoe | Head of Investor Relations | — | — | GBL press-release contact |
Christian Mogge | Investment Partner | — | — | Led BUKO |
Michal Chalaczkiewicz | Investment Partner | — | — | Led Rayner |
Bilge Ogut | Investment Partner | Since January 2026 | 25 years of investment experience | GBL release, 12 Jan 2026 |
Michael Ogrinz | Investment Partner | Since January 2026 | 23 years of investment experience, including 15 at one prior firm (not named in the retrieved excerpt) | GBL release, 12 Jan 2026 |
Joe Topley | CEO, GBL Capital | Since September 2023 | — | GBL Q3 2023 release |
Board of Directors
| Name | Role | Notes |
|---|---|---|
Ian Gallienne | Chairman (since 2 May 2025) | CEO of GBL 2012–2025 (co-MD 2012–2019, sole CEO 2019–2025); son-in-law of the late Albert Frère; architect of the private-asset pivot |
Paul Desmarais, Jr. | Vice-Chairman (since 2 May 2025) | Board member since 1990; Chairman 2019–2025; Power Corporation of Canada |
Johannes Huth | Managing Director | Executive director |
Other directors | Frère- and Desmarais-family representatives, plus independent directors | GBL has a Governance and Sustainable Development Committee, which recommended the 2025 changes, plus customary Audit and Remuneration functions |
Board & Management Changes
| Date | Change |
|---|---|
13 Mar 2025 | Board announces governance overhaul: Desmarais Jr. to step down as Chairman (becoming Vice-Chairman), Gallienne to become Chairman, Huth to become Managing Director |
2 May 2025 | Changes effective at the AGM |
12 Jan 2026 | Appointment of Investment Partners Bilge Ogut and Michael Ogrinz |
Early 2026 | Technology added as a focus sector |
Major Shareholders
| Holder | Stake | Source / comment |
|---|---|---|
Parjointco (50% Frère family group / 50% Power Corporation of Canada) | 47.8% voting interest | Power Corporation, "GBL in numbers 2025". |
GBL treasury shares | 8.0% of capital (10 July 2026) | GBL regulated buyback disclosure |
Free float / institutional investors | Remainder | Top-10 institutional holders not publicly disclosed in retrieved sources |
Insider ownership (directors personally) | Not publicly disclosed in retrieved sources | Family interests held via Parjointco |
Competitive Landscape
Key Competitors
| Peer | Country | Model | Relative positioning vs GBL |
|---|---|---|---|
Investor AB | Sweden | Wallenberg-controlled holding; listed core plus Patricia Industries (private) plus EQT stake | Benchmark "family holding + private arm"; typically trades at a much narrower discount or a premium |
Exor | Netherlands / Italy | Agnelli holding (Ferrari, Stellantis, Philips, etc.) | Larger NAV; high concentration in Ferrari |
Industrivärden | Sweden | Listed-only Swedish holding | Pure listed; lower cost |
Kinnevik | Sweden | Growth / private tech holding | More venture-like |
Wendel | France | Listed holding; pivoting to asset management | Contrasting strategy: Wendel moved into third-party asset management while GBL exited it |
Eurazeo | France | Listed private-equity / asset manager | Third-party fee model |
Sofina | Belgium | Family holding; growth/VC fund-of-funds | Belgian peer; different risk profile |
Ackermans & van Haaren | Belgium | Diversified Belgian holding (marine engineering, banking, real estate) | Belgian peer; operating control model |
Peugeot Invest | France | Peugeot-family holding | Smaller |
HAL Trust | Netherlands | Family-style holding | Concentrated |
CVC, KKR, EQT, Partners Group (sponsors) | Various | Private equity | Competitors for private deals, and partners (CVC) |
Peer Comparison FY2025
| Attribute | GBL | Investor AB | Exor | Wendel |
|---|---|---|---|---|
Controlling shareholder | Frère–Desmarais (Parjointco, 47.8% voting) | Wallenberg foundations | Agnelli (Giovanni Agnelli BV) | Wendel family (WPS) |
Private-asset strategy | Control / co-control, Europe, healthcare and business services | Patricia Industries (100%-owned) | Selective (e.g. healthcare) | Shift to third-party asset management |
Third-party asset management | Exiting (Sienna IM sold 2025–26) | EQT stake | Limited | Core growth strategy |
Leverage | LTV 0.0% (H1 2026) | Low | Moderate | Moderate |
Discount to NAV | 27.9% at YE2025; c.18% at €82.5 vs June NAV per share | — | — | — |



